Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trial
Official title:
Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
The aim of this current study was to assess the therapeutic effects of perindopril and
telmisartan for hypertensive patients with NAFLD and make comparison between the therapeutic
effects of these two kind of drugs.
This study is a randomized parallel control clinical trial which would be carried out in
Nanfang Hospital, Southern Medical University.
About one hundred and eighty patients would be randomly assigned to perindopril,telmisartan
and amlodipine three groups.
Inclusion criteria:
18-70 years old patients who were diagnosed with mild-moderate hypertension and NAFLD; The
patients did not take ACEIs or ARBs drugs six weeks before the inclusion; Patients agreed to
participate in the trial and signed the informed consent.
Exclusion criteria:
There are no coexisting causes for chronic liver disease, such as viral,
alcoholic,drug-induced and autoimmune liver diseases; Patients with diabetes mellitus;
Patients with serious primary diseases; Patients with mental disorder or can not take the
medicine regularly; Pregnancy and nursing mothers; Allergic constitution or intolerance to
ACEIs or ARBs drugs. Outcome measures include Cap value of FibroScan,angiotensin
II,IL-18，IL-1β,aminotransferase,lipids and HOMA-IR.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02244944 -
Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD
|
Phase 2 | |
| Recruiting |
NCT01544751 -
Nonalcoholic Fatty Liver Disease (NAFLD) Pharmacological Treatment: Metformin Versus Atorvastatin
|
N/A | |
| Recruiting |
NCT03572465 -
Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
|
||
| Enrolling by invitation |
NCT04059029 -
Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
|
||
| Terminated |
NCT01930123 -
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease
|
Phase 2 | |
| Recruiting |
NCT01705522 -
Multimodal Approach in IBD Patients
|
||
| Recruiting |
NCT03525769 -
Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes
|
||
| Recruiting |
NCT06024408 -
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
|
Phase 1 | |
| Completed |
NCT01265498 -
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
|
Phase 2 | |
| Completed |
NCT01529268 -
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
|
Phase 2/Phase 3 | |
| Completed |
NCT02217345 -
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
|
Phase 2 | |
| Completed |
NCT03486899 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis
|
Phase 2 | |
| Completed |
NCT02781584 -
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT03486912 -
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
|
Phase 2 | |
| Completed |
NCT02196831 -
Tesamorelin Effects on Liver Fat and Histology in HIV
|
N/A | |
| Withdrawn |
NCT03451279 -
A Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis
|
Phase 2 | |
| Completed |
NCT02044523 -
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
|
||
| Completed |
NCT03836443 -
Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease
|
N/A | |
| Completed |
NCT03042767 -
Anti-LPS Antibody Treatment for Pediatric NAFLD
|
Phase 2 | |
| Completed |
NCT03459079 -
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
|
Phase 2 |